Aptevo Therapeutics (APVO) Misses Q3 EPS by 15c

Aptevo Therapeutics (NASDAQ: APVO) reported Q3 EPS of ($1.50), $0.15 worse than the analyst estimate of ($1.35).

For earnings history and earnings-related data on Aptevo Therapeutics (APVO) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
• BMO Capital Reiterates Outperform Rating on CMS Energy (CMS)